Head-to-head · WeighScore
Mevo Health vs PlushCare
The verdict
PlushCare takes it — 74.5/100 to 60.2/100.
PlushCare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Established virtual primary-care telehealth platform (subsidiary of Transcarent, Inc., a Delaware corporation, alongside Accolade, 2nd.MD, and 98point6 by Transcarent).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Mevo Health | PlushCare |
|---|---|---|
| WeighScore | 60.2/100 | 74.5/100 |
| Grade | C | C |
| Scorecard rank | #326 | #63 |
| Semaglutide | $199/mo (all doses, compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | $259/mo (all doses, compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #326 · C
Strengths
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
Where it loses points
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Graded #63 · C
Strengths
- Available in all 50 states
- Appointments with US board-certified physicians, not nurse practitioners only
- Virtual primary care — the same doctor can manage GLP-1s alongside other health needs
- Owned by Transcarent, a venture-backed health platform with a named corporate parent
Where it loses points
- Facing a California class action alleging deceptive subscription enrollment and unauthorized charges after cancellation
- GLP-1 prescribing is up to the clinician at the visit — not guaranteed at signup
- BBB complaints center on the membership cancellation process
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.